Pacific Biosciences

PACB SEC CIK 1299130 LEI 529900F1BWRE1M0KZN89
Follow Pacific Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $40.6M +5.5% vs same quarter last year
Net income −$37.8M +0.4% vs same quarter last year
EPS, diluted −$0.12 +7.7% vs same quarter last year
Operating cash flow −$37.6M −101% vs same quarter last year
Revenue by quarter
$39.2M
$37.2M
$39.8M
$38.4M
$44.6M
$37.2M
$39M
$40.6M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$600M−$400M−$200M$0$200M$400MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$160M−$546.4M
FY24$154M−$309.9M
FY23$200.5M−$306.7M
FY22$128.3M−$314.2M
FY21$130.5M−$181.2M
FY20$78.9M$29.4M
FY19$90.9M−$84.1M
FY18$78.6M−$102.6M
FY17$93.5M−$92.2M
FY16$90.7M−$74.4M
FY15$92.8M−$31.7M
FY14$60.6M−$66.2M
FY13$28.2M−$79.3M
FY12$26M−$94.5M
FY11$33.9M−$109.4M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−400%−200%0%200%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2528.6%−346.2%−341.5%
FY2424.2%−308%−201.2%
FY2326.3%−166.8%−153%
FY2238.2%−239.4%−244.9%
FY2145.1%−161.2%−138.8%
FY2041.3%−132.3%37.3%
FY1938%−110.6%−92.6%
FY1831.9%−128.4%−130.4%
FY1737.1%−96.1%−98.6%
FY1648.7%−78.5%−82%
FY1557.6%−31.4%−34.2%
FY1438.6%−103.7%−109.2%
FY1322.8%−275.2%−281.4%
FY123.6%−363.1%−363.6%
FY1138.5%−324.1%−323%
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0$100MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$113.9M
FY24−$212.2M
FY23−$268M
FY22−$280M
FY21−$117.1M
FY20$18.5M
FY19−$81.1M
FY18−$68.3M
FY17−$78M
FY16−$76.1M
FY15−$50.9M
FY14−$53.1M
FY13−$30.7M
FY12−$78.5M
FY11−$112.3M